LeMaitre CFO granted dividend-equivalent rights

Q: What insider transactions did LMAT’s CFO report on September 3, 2026?

LMAT’s Chief Financial Officer Dorian Paul LeBlanc reported two acquisitions of Dividend Equivalent Rights on September 3, 2026. These awards arose from dividends on earlier RSU grants and are the economic equivalent of additional shares of common stock.

Q: How many Dividend Equivalent Rights did the LMAT CFO acquire in this Form 4?

The CFO acquired 2.8858 Dividend Equivalent Rights from one RSU grant and 3.6735 from another, both on September 3, 2026. Each Dividend Equivalent Right is the economic equivalent of one share of LMAT common stock.

Q: What are Dividend Equivalent Rights in the context of LMAT (LMAT) equity awards?

For LMAT, each Dividend Equivalent Right is disclosed as the economic equivalent of one share of the company’s common stock. They accrue on outstanding RSU awards when dividends are paid and vest proportionately with the underlying RSUs.

Q: Were the LMAT CFO’s September 3, 2026 transactions under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not marked as a plan transaction, and the footnotes describe the awards as Dividend Equivalent Rights accruing on RSU grants, not as trades executed under a trading plan.

LMAT’s CFO received additional dividend-equivalent rights linked to earlier RSU awards, modestly increasing his equity-based compensation.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

LEMAITRE VASCULAR INC (symbol: LMAT) is the issuer of record for a Form 4 filing submitted to the SEC. LeBlanc Dorian Paul reported acquisition or exercise transactions in this Form 4 filing.

LEMAITRE VASCULAR INC (LMAT) reported that its Chief Financial Officer, Dorian Paul LeBlanc, received small awards of additional Dividend Equivalent Rights on September 3, 2026 tied to prior restricted stock unit (RSU) grants. The awards reflect accrued dividend equivalents and are the economic equivalent of additional shares of common stock.

Insider Trade Summary

Grant/Award: 6.5593 shares

Grant/Award 2 txns

Insider LeBlanc Dorian Paul

Role Chief Financial Officer

Type	Security	Shares	Price	Value
Grant/Award	Dividend Equivalent Rights ^F1	2.8858	$0.00	$0.00
Grant/Award	Dividend Equivalent Rights ^F2	3.6735	$0.00	$0.00

Holdings After Transaction: Dividend Equivalent Rights — 26.2762 contracts (Direct)

Footnotes (2)

F1. These dividend equivalent rights accrued on a restricted stock unit award granted on 3/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.
F2. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

Key Figures

Dividend Equivalent Rights acquired (grant 3/10/2025): 2.8858 rights Dividend Equivalent Rights acquired (grant 12/10/2025): 3.6735 rights Total derivative transactions: 2 transactions +1 more

4 metrics

Dividend Equivalent Rights acquired (grant 3/10/2025) 2.8858 rights Accrued on RSU award granted March 10, 2025; reported September 3, 2026

Dividend Equivalent Rights acquired (grant 12/10/2025) 3.6735 rights Accrued on RSU award granted December 10, 2025; reported September 3, 2026

Total derivative transactions 2 transactions All were acquisitions of Dividend Equivalent Rights on September 3, 2026

Per-right economic equivalence 1 common share per right Each Dividend Equivalent Right is the economic equivalent of one share of LMAT common stock

Key Terms

Dividend Equivalent Rights, restricted stock unit award, economic equivalent

3 terms

Dividend Equivalent Rights financial

"These dividend equivalent rights accrued on a restricted stock unit award"

Dividend equivalent rights are promises that mirror the cash payments shareholders get from a company’s profits, but they are paid to holders of certain awards (like stock options or restricted stock units) rather than to actual shares. Think of them as a paycheck top‑up that matches dividends while the award is not yet a real stock, and they matter to investors because they add to employee compensation costs and potential share dilution, affecting company profitability and per‑share value.

restricted stock unit award financial

"These dividend equivalent rights accrued on a restricted stock unit award granted"

A restricted stock unit award is a promise by a company to give an employee a specified number of company shares at a future date if certain conditions are met, such as staying with the company or hitting performance goals. For investors, these awards matter because they can increase the total number of shares outstanding when converted, diluting existing holders, and they align employees’ incentives with shareholders’ interests much like giving a rising bonus that becomes real only after conditions are satisfied.

economic equivalent financial

"Each dividend equivalent right is the economic equivalent of one share"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did LMAT’s CFO report on September 3, 2026?

LMAT’s Chief Financial Officer Dorian Paul LeBlanc reported two acquisitions of Dividend Equivalent Rights on September 3, 2026. These awards arose from dividends on earlier RSU grants and are the economic equivalent of additional shares of common stock.

How many Dividend Equivalent Rights did the LMAT CFO acquire in this Form 4?

The CFO acquired 2.8858 Dividend Equivalent Rights from one RSU grant and 3.6735 from another, both on September 3, 2026. Each Dividend Equivalent Right is the economic equivalent of one share of LMAT common stock.

What are Dividend Equivalent Rights in the context of LMAT (LMAT) equity awards?

For LMAT, each Dividend Equivalent Right is disclosed as the economic equivalent of one share of the company’s common stock. They accrue on outstanding RSU awards when dividends are paid and vest proportionately with the underlying RSUs.

Which LMAT RSU grants generated these new Dividend Equivalent Rights for the CFO?

One block of Dividend Equivalent Rights accrued on an RSU award granted on March 10, 2025, and the other accrued on an RSU award granted on December 10, 2025. In each case, the Dividend Equivalent Rights vest proportionately with the related RSU award.

Were the LMAT CFO’s September 3, 2026 transactions under a Rule 10b5-1 trading plan?

No. The filing’s Rule 10b5-1 checkbox is not marked as a plan transaction, and the footnotes describe the awards as Dividend Equivalent Rights accruing on RSU grants, not as trades executed under a trading plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 09/08/2026 - 04:47 PM Accepted by SEC EDGAR 09/08/2026 - 04:46 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

LeBlanc Dorian Paul

(Last)

(First)

(Middle)

C/O LEMAITRE VASCULAR, INC.

63 SECOND AVENUE

(Street)

BURLINGTON

MASSACHUSETTS

01803

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LEMAITRE VASCULAR INC [ LMAT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Financial Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Dividend Equivalent Rights	⁽¹⁾	09/03/2026		A		2.8858		⁽¹⁾	⁽¹⁾	Common Stock	2.8858	$0	16.7834	D
Dividend Equivalent Rights	⁽²⁾	09/03/2026		A		3.6735		⁽²⁾	⁽²⁾	Common Stock	3.6735	$0	9.4928	D

Explanation of Responses:

1. These dividend equivalent rights accrued on a restricted stock unit award granted on 3/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

2. These dividend equivalent rights accrued on a restricted stock unit award granted on 12/10/2025 and vest proportionately with such award. Each dividend equivalent right is the economic equivalent of one share of the Issuer's common stock.

	/s/ Douglas G. Bush, Attorney-in-fact	09/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

LeMaitre CFO granted dividend-equivalent rights

Rhea-AI Filing Summary

Positive

Negative